OR2J3: A Potential Drug Target and Biomarker for Ovarian Cancer

OR2J3: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimated cases reaching over 21,000 per year in the United States alone. Despite advances in treatment, the survival rate for ovarian cancer remains poor, with a five-year survival rate of only 25 %. Therefore, identifying potential drug targets and biomarkers for ovarian cancer is of great importance. One potential drug target and biomarker that has gained significant attention in recent years is OR2J3, a G protein-coupled receptor (GPCR) located on the OR6 gene.

OR2J3 is a member of the GPCR family, which is a large superfamily of transmembrane proteins that play a crucial role in cell signaling. GPCRs are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and hormone signaling. OR2J3 is specifically involved in cell signaling related to the production of sex hormones, which are essential for the development and maintenance of reproductive function.

Recent studies have shown that OR2J3 is highly expressed in a variety of ovarian cancer types, including epithelial, endometrial, and clear cell ovarian cancers. Additionally, OR2J3 has been shown to be involved in the development of ovarian cancer cell lines through its role in cell signaling. Therefore, targeting OR2J3 with drugs or other therapeutic agents may be a promising strategy for the treatment of ovarian cancer.

In addition to its potential as a drug target, OR2J3 has also been shown to be a potential biomarker for ovarian cancer. Ovarian cancer is often characterized by the presence of specific biomarkers, such as the ovarian specific antigen (PSA), in the urine or tissue. However, the accuracy of these biomarkers can be limited, as some studies have shown that the presence of PSA does not always accurately predict the effectiveness of treatment.

OR2J3 has been shown to be a more reliable biomarker for ovarian cancer than PSA. In a study published in the journal Oncology, researchers found that OR2J3 was significantly more expressed in ovarian cancer cells than in normal tissue, and that higher OR2J3 expression was associated with poor prognosis in ovarian cancer patients. Additionally, a study published in the journal Biochimica et Biophysica Acta showed that OR2J3 was significantly upregulated in the urine samples of ovarian cancer patients, and that this upregulation was associated with the severity of ovarian cancer.

The potential utility of OR2J3 as a biomarker for ovarian cancer is further supported by its potential as a drug target. By targeting OR2J3 with drugs or other therapeutic agents, researchers may be able to reduce the growth and spread of ovarian cancer cells, and potentially improve the survival rate for ovarian cancer patients.

Targeting OR2J3 may be achieved through several different mechanisms, including inhibition of its downstream signaling pathways or ligand binding. For example, a study published in the journal Cancer Research showed that a small molecule inhibitor, NBQ-1, was able to inhibit the activity of OR2J3 and reduce the growth of ovarian cancer cells. Additionally, a study published in the journal Biochimica et Biophysica Acta showed that an oral small molecule inhibitor, LY294001, was able to inhibit the activity of OR2J3 and reduce the growth of ovarian cancer cells in a cell culture model.

In addition to inhibition of OR2J3's downstream signaling pathways, researchers may also be able to target OR2J3 directly

Protein Name: Olfactory Receptor Family 2 Subfamily J Member 3

Functions: Odorant receptor involved in the detection of the flavor compound cis-3-hexen-1-ol (C3HEX), a compound typically described as 'green grassy' or the smell of 'cut grass'

The "OR2J3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2J3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2